Why the study?
Clopidogrel resistance or heightened platelet reactivity may lead to suboptimal antiplatelet effects and thrombosis, but data on its prevalence in large cohorts undergoing coronary or endovascular interventions are limited.
Answers are grounded in this paper and cite their sources.
Clopidogrel resistance is present in nearly half of patients undergoing vascular and coronary interventions, suggesting it is more common than previously appreciated.
OBJECTIVES: "Clopidogrel resistance," also defined as heightened platelet reactivity (HPR) while on clopidogrel therapy, may lead to a sub-optimal antiplatelet effect and a potential thrombotic event. There is limited literature addressing the prevalence of HPR in a large cohort of patients receiving either coronary or endovascular interventions. METHODS: In a large integrated healthcare system, patients with a P2Y12 reaction units (PRU) test were identified. HPR was defined as a PRU ≥ 200 during clopidogrel therapy. Vascular and coronary interventions were identified utilizing CPT codes, HPR prevalence was calculated, and Fischer's exact test was used to determine significance. CONCLUSION: "Clopidogrel resistance" or HPR was found to be present in nearly half of patients with cardiovascular disease undergoing intervention. Our data suggest HPR is more common in the cardiovascular patient population than previously appreciated. Evaluating patients for HPR is both inexpensive ($25) and rapid (< 10 min). Future randomized studies are warranted to determine whether HPR has a clinically detectable effect on revascularization outcomes.
No takes yet. Share an insight, caveat, or question.
Berenson et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: